Olatz Etxaniz

5PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 15, 2026
Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.

|Feb 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Xavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero

|Feb 15, 2022
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.

Juan Carlos Pardo, Tamara Sanhueza, Vicenç Ruiz de Porras

|May 05, 2021
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Vicenç Ruiz de Porras, Juan Carlos Pardo, Lucia Notario

|Sep 09, 2017
IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Olatz Etxaniz, Cristina Carrato, Itziar de Aguirre

Pageof 1

Frequent Collaborators

3 joint publications

Vicenç Ruiz de Porras

1 joint publications

Enrique Grande

1 joint publications

Lidia Estudillo

1 joint publications

Xavier Garcia-Del-Muro